This is an author produced version of a paper published in Journal of molecular medicine-JMM. This paper has been peer-reviewed but does not include the final publisher proof-corrects or journal pagination.

Citation for the published paper:
Sonja Oehmcke, Heiko Herwald

"Contact system activation in severe infectious diseases."

Journal of molecular medicine-JMM 2010 88, 121 - 126

http://dx.doi.org/10.1007/s00109-009-0564-y

Access to the published version may require journal subscription.
Published with permission from: Springer
Contact System Activation in Severe Infectious Diseases

Sonja Oehmcke# and Heiko Herwald

From the Department of Clinical Sciences, Division of Infection Medicine, Lund University, SE-22184 Lund, Sweden.

#To whom correspondence should be addressed: Department of Clinical Sciences, Division of Infection Medicine, BMC, B14, Lund University, Tornavägen 10, SE-22184 Lund, Sweden, Phone +46-46-2228592, Fax +46-46-157756, e-mail sonja.oehmcke@med.lu.se
Abstract

Hemostasis is a sensitive and tightly regulated process, involving vascular endothelium and blood cells as well as factors of the coagulation and fibrinolytic cascades. In severe and invasive infectious diseases the equilibrium between the procoagulant and anticoagulant status of the host may change dramatically and can induce life-threatening complications. A growing body of evidence suggests that the contact system, also known as the intrinsic pathway of coagulation or kallikrein/kinin system, participate in these processes. Contact activation leads to the release of the highly potent proinflammatory peptide bradykinin and initiates the intrinsic pathway of coagulation. Several studies have shown a systemic activation of the contact system in animal models of severe bacterial infections and similar findings were also reported when monitoring patients suffering from sepsis, severe sepsis, or septic shock. Complications resulting from a systemic activation of the contact system are pathologically high levels of bradykinin, consumption of contact factors, and a subsequent induction of inflammatory reactions. These conditions may contribute to serious complications such as hypotension and vascular leakage. Here we summarize the state of the art in this field of research with a focus on the contact system and we also discuss a potential role for the contact system as a target for the development of novel antimicrobial strategies.
Introduction

Sepsis, severe sepsis, and septic shock are complications derived from bacterial infections that are the second leading cause of death among patients in non-coronary intensive care units and the 10th leading cause of death in the United States [1]. Despite treatment with antibiotics and an improved intensive care system, the incidence of sepsis and the number of sepsis-related deaths are increasing and they are associated with mortality rates between 30 and 70% [2]. The molecular mechanisms behind the pathogenesis of these life-threatening conditions are still not fully understood. A growing body of evidence, however, suggests that the interaction between bacterial pathogens and the host defense machinery results in an uncontrolled and overwhelming inflammatory response. This includes a systemic activation of proteolytic host cascades such as the complement and coagulation cascades as well as the contact system, also known as the kallikrein/kinin system or intrinsic pathway of coagulation [3].

The contact system

Once activated the contact system is involved in the regulation of hemostatic and inflammatory processes [4, 5]. The system contains 4 components: three serine proteinases: factor XI (FXI), factor XII (FXII), plasma kallikrein, and the non-enzymatic co-factor, high molecular weight kininogen (HK), respectively. The latter protein consists of six domains, of which domain 1 – 3 are cystatin-like. The bradykinin sequence is found in domain 4, and domain 5 carries a zinc-binding site and a binding site for negatively charged surfaces [4-7]. As early as 1995 it was shown that HKH20, a peptide derived from HK domain 5 (amino acids 479 to 498), spanning the binding site for negatively charges surfaces, is able to interact with M protein, an important streptococcal virulence factor [6]. Thereafter, it was also reported that HKH20 mimics the HK binding site to many eukaryotic cell types [8-10], binds to lipopolysaccharide [11], and has antimicrobial activity [12]. In addition another HK-derived peptide (amino acids 420 to 513) covering the HKH20 sequence was found to down-regulate endothelial cell proliferation and migration and inhibit angiogenesis [13]. Finally, domain 6 mediates the binding to plasma kallikrein and FXI [14].

The four contact factors normally circulate in the bloodstream or are bound to the surface of different cell types, including endothelial cells, platelets and polymorphonuclear neutrophils (PMNs). Negatively charged surfaces such as kaolin and dextran-sulfate as well as nucleotides (DNA and RNA) have been reported to assemble and activate the contact system [10, 15-17]. While the molecular
mechanisms leading to a contact activation on kaolin and dextran-sulfate are more or less understood, there are controversial reports addressing the mode of activation on cellular surfaces. Therefore, the latter will not be discussed in this article. FXII bound to kaolin is converted into an active proteinase (FXIIa) by autoactivation. This is followed by a FXIIa-mediated activation of plasma kallikrein, a process referred to as limited proteolysis. Plasma kallikrein in turn is able to increase the activity of FXIIa, which then enables FXIIa to activate FXI and subsequently the intrinsic pathway of coagulation (Fig.1) eventually leading to the formation of a fibrin network.

Inflammatory reactions are evoked by the processing of HK via plasma kallikrein, resulting in the release of bradykinin (BK) from its precursor. BK is a potent multifunctional pro-inflammatory peptide consisting of nine amino acids. Many effects of BK are induced by its ability to trigger the induction of second-generation mediators such as nitric oxide, prostaglandins and leukotrienes. In addition BK is involved in many other processes such as the regulation of blood pressure, induction of fever, increase of vascular permeability and capillary leakage, edema formation, and hypotension [4, 5]. Notably, the half-life of BK in the circulation is extremely short (< 10 seconds) and thus, increased levels of BK in patients with various underlying diseases are difficult to monitor. There are, however, two conditions that are associated with high levels of BK namely hereditary angioedema (caused by a deficiency of C1-inhibitor, an inhibitor of the contact and the complement system) and severe infectious diseases (for reviews see [18, 19]).

Sepsis and Coagulation

Sepsis is defined as a systemic inflammatory response syndrome (SIRS) with an underlying infection. Complications from these life-threatening conditions are often expanded when the initial appropriate host response to the invading pathogen is amplified and becomes deleterious. Clinical symptoms of the onset are frequently conflictive (fever or hypothermia, tachycardia, leukocytosis or leucopenia), and if untreated, patients may develop respiratory or renal failure, coagulopathy and non-responsive hypotension. The immunologic reactions under these conditions are complex and can alter over time. The early proinflammatory response is characterized by an overwhelming stimulus and triggers PMNs and macrophages to an excessive production of cytokines, chemokines, and other proinflammatory mediators. Other complications, such as secondary ischemia (shock) and hypoxia (lung injury) can also amplify the proinflammatory response [20]. This boost of inflammatory reactions may lead to a shift from a normally beneficial inflammatory response to hyper-inflammatory and counterproductive reactions, which eventually
cause more damage than the host can tolerate. It is now believed that the initial hyper-inflammatory phase accounts for some early deaths, although most patients die at later stages due to their prolonged immunosuppressive state [21].

Studies of host-parasite interactions taking place in the circulation have significantly contributed to our understanding of the molecular mechanisms that lead to the induction of systemic inflammatory reaction. Host effectors systems that are of interest here are the contact-, complement-, fibrinolytic-, and coagulation systems. The latter is activated by the induction of tissue factor (TF) expression on mononuclear and endothelial cells, which is often triggered by bacteria or bacterial products [22]. An up-regulation of TF on the surface of these cells can lead to a systemic activation of the coagulation system that may progress to additional complications such as disseminated intravascular coagulation (DIC). DIC is characterized by the formation of microthrombi in microvasculature [23]. At the initial stage clot formation occurs intra- and extravascularly due to thrombin activation (hypercoagulopathy) and is followed by a consumption of coagulation factors combined with a platelet dysfunction (hypocoagulability). This chain of events leaves the patients in a paradoxical situation, where microvascular thrombus formation causes a perturbation in the microcirculation, leading to multiple organ failure, complicated by impairment of fibrinolysis. On the other hand patients experience a high risk for severe bleeding due to depletion of coagulation factors and platelets [24].

**Contact activation in severe infectious diseases**

With regard to the role of the contact system in severe infectious diseases it should be noted that it was already in 1970 reported that patients with hypotensive sepsis have significantly lower levels of contact factors in their blood than patients with sepsis alone [25]. Since then, several studies have been published showing that systemic contact activation has been found in patients with severe sepsis, septic shock and sepsis combined with SIRS and that this is often combined with a massive release of BK and a consumption of contact factors [26-28]. Notably, low levels of plasma kallikrein, FXII and HK during sepsis correlate with a fatal outcome of the disease [26, 29].

Until recently is was generally accepted that the contact system plays a secondary role in hemostasis, since patients with deficiencies in FXII, plasma kallikrein, or HK do not suffer from bleeding disorders. This point of view changed when the first data on FXI and FXII deficient mice were published and it was found that contact activation contributes to pathological thrombus formation in response to vessel injury
Whether the contact system contributes to pathologic coagulation disorders in severe infectious diseases is controversial and discussed. For instance, Pixley and colleagues reported that contact activation occurs in patients with DIC [32]. Pronounced activation of the system was also seen in children with meningococcal septic shock [33, 34] and in patients with streptococcal toxic shock syndrome (STSS) [35]. On the other hand it has been found that patients with STSS but without a bleeding tendency, had a prolonged aPTT [35], implying that contact activation has occurred. The latter findings are in line with an experimental baboon model of lethal E. coli bacteremia, showing that systemic contact activation is not combined with DIC, but with fatal hypotension, probably caused by the release of BK [36, 37]. It is noteworthy to mention that animals experienced an initial hypotension that was reversed, when treated with a human antibody against FXII and extended the life of the baboons [36]. However, more studies are required to unravel the role of the contact system in the induction of coagulation disorders in severe infectious diseases.

**Contact activation and inflammation**

The release of BK from HK is responsible for evoking inflammatory reactions [38]. There are two types of kinin receptors in humans, termed B1 and B2 receptors. Mice lacking both receptors have normal blood pressure and cardiac morphology and they are unable to respond to stimulation with kinins [39]. Importantly, lipopolysaccharide (LPS) challenge in B1B2−/− mice does not affect the blood pressure in these animals, while blood pressure was markedly decreased in wild-type animals [39]. Other studies have shown a protective effect of kinin antagonists in a lethal LPS model in rats [40]. With regards to the molecular mechanisms leading to the induction of these inflammatory reactions, Fischer et al. conducted experiments showing that BK-induced vasoconstriction in a rat LPS model can be prevented by the application of cyclooxygenase inhibitors and is dependent on the inducible nitric oxide synthase [41, 42]. These findings imply that the induction of second-generation mediators by kinins significantly contribute to the inflammatory reactions seen in the LPS challenged animals. Interestingly, many bacterial proteinases have evolved mechanisms to trigger the release of BK from HK, either by cleaving HK directly or by activating PK. One of the first reports was already published in 1984 by Matsumoto and colleagues who described a metallo protease from *Serratia marcescens* with plasma kallikrein-like properties [43]. Since then, bacterial proteinases from many other bacterial species have been described to activate the contact system in one way or another (for a review see [44]). It has been suggested that the vascular
permeability induced by the released kinins promotes an influx of plasma into the site of infection that serves as nutrients and facilitates spreading of the microorganisms within the infected host [44].

Contact activation caused by microorganisms

As early as 1983 it was shown by Kalter et al. that LPS of Gram-negative bacteria as well as peptidoglycan and teichoic acid of Gram-positive bacteria have the ability to induce activation of the contact system [45]. While the LPS binding-site in HK was recently resolved [46], no information on the interaction sites between peptidoglycans and teichoic acid with contact factors has been published to date. Subsequent studies have shown that bacterial surface proteins, such as M protein of Streptococcus pyogenes or thin aggregative fimbriae expressed by Escherichia coli and Salmonella, are able to bind and assemble contact factors on their surfaces and trigger the activation of the system [6, 47]. An activation of the contact system by Staphylococcus aureus and Rickettsia rickettsii has also been described [7, 48] although the bacterial proteins that promote the binding to the contact factors have not yet been identified. In addition, and as mentioned above, many bacterial proteinases have been described to cleave HK and release BK, and recently it has been reported that fungal pathogens also (Candida species) interact with factors of the contact system [49].

Contact System Inhibition – a potential therapeutic intervention?

One can wonder whether the contact system is an interesting target for drug development, as it also has protective effects. For instance, it plays an important role in innate immunity via the generation of HK-derived antibacterial peptides and kinin induced recruitment of neutrophils [50-52]. However, these responses take place at an early stage and are most likely restricted to the site of infection, while under systemic conditions a massive activation of the contact system may lead to the release of pathologic levels of kinins and a consumption of contact factors (for a review see [26]). Notably, low levels of some contact factors are an indication of an unfavorable outcome of the disease [26]. The prevention of a systemic activation could therefore benefit seriously ill patients. Kinins are potent inflammatory mediators, causing symptoms such as increased vascular permeability, vascular leakage, hypotension and edema formation, which are a hallmark of severe infectious diseases. Kinin receptors are therefore attractive targets for drug development. Two receptors (B1R and B2R) have been described in humans, of which both have completely different pharmacologic profiles (for a review
B2R is constitutively expressed by most cell types and rapidly internalized upon BK binding [53], while B1R is generally expressed at a low level in normal tissue, but up-regulated upon stimulation with proinflammatory agents such as LPS or endotoxins from S. aureus and S. pyogenes [54-56]. A number of kinin receptor antagonists have been developed and successfully used in animal models [57]. However, so far only a B2R antagonist (Deltibant) has been used in clinical trials for sepsis [58]. The drug was used in patients with SIRS and presumed sepsis in a randomized, double-blind, placebo-controlled trial. Deltibant observed no significant effect on risk-adjusted 28-day survival, but posthoc analysis of risk-adjusted 7-day survival showed a non-significant trend toward improvement. Furthermore, the 28-day risk-adjusted survival in the prospectively defined subset of patients with Gram-negative infections showed a statistically significant improvement [58]. Considering the important role of the B1R in infectious diseases [59], theoretically, a combination of B1R and B2R antagonists could be an interesting alternative approach for a clinical trial.

C1 inhibitor is a member of the family of serine proteinase inhibitors and a major regulator of the complement and contact systems. It has been reported that levels of proteolytically inactivated C1 inhibitor are increased in septic patients [60]. Notably, treatment with C1 inhibitor during sepsis attenuated contact activation and had a beneficial effect on hypotension and renal dysfunction [61-63]. The results from clinical studies, therefore, indicate that therapeutic administration of C1 inhibitor may be safe, even though major bleedings have been observed in patients as compared to the control groups [62]. It should be noted that C1 inhibitor inhibits serine proteases irreversibly and may also block other proteases from the coagulation cascade, if applied in therapeutic doses.

A completely different mode of contact system inhibition was recently reported in a mouse model of invasive streptococcal infections. In this study a synthetic peptide derived from domain 5 of HK, resembling the binding site to eukaryotic and bacterial surfaces (see above), was shown to prevent activation of the contact system on these surfaces [64]. Treatment with the peptide protected mice with invasive Streptococcus pyogenes infection from lung damage and, in combination with clindamycin, the peptide also significantly improved the overall survival. However, the peptide has not been used in clinical trials yet.

**Concluding remarks**

Therapies in sepsis, severe sepsis, and septic shock, which are entirely based on antibiotics, are combined with a high risk to fail, and thus, there is an urgent need for
novel antimicrobial strategies. Concepts focusing on the prevention of pathophysiological mechanisms in severe infectious diseases, such as the systemic activation of important host effector systems, are therefore promising and may have a considerable impact. For instance, treatment with activated protein C (APC) has been found to reduce the mortality in severe sepsis patients [65]. However, APC administration is combined with severe side effects (bleeding) and, thus, its application is restricted to patients at high risk of death.

Patients with deficiencies in FXII, plasma kallikrein, or HK do not experience severe bleeding disorders. The inhibition of the contact system at the initial stage of an infection is therefore an interesting therapeutic approach to prevent hyper-inflammatory reactions. This concept is in line with findings that the treatment of sepsis patients with C1 inhibitor results in a beneficial clinical outcome. However, the study also showed that patients still suffer from severe bleedings, probably because C1 inhibitor also targets other coagulation factors apart from plasma kallikrein. It is therefore tempting to speculate that more specific contact inhibitors with a saver pharmacologic profile are promising candidates for the development of novel antimicrobial therapies.
Acknowledgements
This work was supported in part by the foundations of Alfred Österlund, Crafoord, Greta and Johan Kock, the Blood and Defence Network and the Vascular Wall Programme at Lund University, the Medical Faculty, Lund University, the Swedish Research Council, and Hansa Medical. Hansa Medical, that in part funded this study has filed patent applications on HKH20. SO and HH are listed as inventors and the applications are pending.

Keywords
Sepsis, coagulation, contact system, Streptococcus pyogenes
References


54. Schremmer-Danninger E, Offner A, Siebeck M, Roscher AA (1998) B1 bradykinin receptors and carboxypeptidase M are both upregulated in the aorta of pigs after LPS infusion. Biochemical and biophysical research communications 243: 246-252. DOI S0006-291X(97)97999-7 [pii]


Intrinsic pathway of coagulation

Negatively charged surface

F XI
HK

F XIIa
PK
HK

Bradykinin
Fig. 1: The contact system. Assembly of contact system factors on a negatively charged surface activates FXII. FXII activates FXI that triggers the intrinsic pathway of coagulation and plasma kallikrein. Plasma kallikrein cleaves HK, followed by the release of the proinflammatory peptide BK.